As of April 2014, it is in the 7th cohort of patients. The dose escalation continues to progress as they have not yet observed any DLTs or the MTD (Filing 10-Q , CellCeutix, MAY 12, 2014, View Source [SID:1234500521]). The company anticipates this endpoint will be reached in the second half of 2014.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!